A new study shows that weight loss drug semaglutide can help patients lose weight and keep it off for good. The drug is very potent, and it is delivered via an injection. This may make the treatment easier for patients, as they will have a reminder to keep up with their weight loss program every week. It could also help patients to stick to their dietary and exercise plans more easily.
The drug, which is an injectable treatment for diabetes, shows huge promise for those suffering from obesity. Its results suggest that it can lower the risk of type 2 diabetes by 60% in obese and overweight people. It also reduced the risk of prediabetes, which is the condition where people have high blood sugar levels.
The FDA approved semaglutide in the United States last year. It is the first drug based on the GLP-1 hormone. Scientists at Merck studied hundreds of drugs to find a way to block GLP-1 receptors, which help control appetite. Moreover, the FDA didn’t find any serious side effects of the drug.
Eli Lilly and other drug companies are trying to find a new drug to fight obesity. But the current five FDA-approved drugs have their drawbacks. For instance, phentermine is highly effective but only works for a short period. And once the drug is stopped, the user often regains their lost weight. The most effective treatment for obesity is bariatric surgery, which allows obese people to lose 25 to 30 percent of their body weight.
Other promising weight loss drugs are the analogs of satiety and hunger hormones. A former Lilly researcher who sold his start-ups to Novo Nordisk is developing these small proteins for use in metabolic diseases and weight loss. These small proteins act by modulating the GIP and GLP-1 receptors.
The FDA has approved a new weight loss drug, Wegovy, for use in patients with Type 2 diabetes. This drug works by telling the pancreas to produce more insulin, which helps control blood sugar levels and lead to weight loss. This new drug is the first of its kind, and Novo Nordisk has designed trials to study its effects on obesity.
The cost of Wegovy is a major concern, and Novo Nordisk has not disclosed its list price. Currently, Saxenda costs around $1,300 per month without insurance. Although wegovy can reduce a person’s weight to a modest extent, the drug’s high cost could present major challenges for its uptake.